|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Evaluating the Efficacy of Sabizabulin in The Treatment of Metastatic Castration-Resistant Prostate Cancer
|
|
Robert Dreicer, MD, MS, MACP, FASCO
|
| Joining Alicia Morgans is Robert Dreicer highlighting a currently enrolling Phase III trial of sabizabulin, an oral cytoskeleton disruptor in mCRPC. The VERACITY trial s a blinded trial of 245 patients randomized to two to one drug, to the alternative ARI. Dr. Dreicer describes the rationale for the trial, the trial design, and the eligibility criteria.
|
|
|
|
|
|
|
|
|
|
|
|
| PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients |
| Michael Morris, MD |
| Alicia Morgans and Michael Morris, discuss the PSMAfore trial in progress. PSMAfore is a phase 3 study evaluating the patient population that just precedes VISION in terms of place on the timeline of metastatic CRPC. |
|
|
|
|
|
|
|
|
|
|
|
|
Combined Testosterone Therapy with Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer
|
|
Michael Schweizer, MD
|
| In this UroToday discussion between Alicia Morgans and Michael Schweizer, they discuss a single-center phase II trial that combined testosterone therapy with olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
|
|
|
|
|
|
|
First-in-Human Study of FOR46 in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
|
Rahul Aggarwal, MD
|
| Rahul Aggarwal joins Alicia Morgans describing this first-in-human study of the safety and preliminary efficacy of FOR46 in metastatic castration-resistant disease (mCRPC) patients.
|
|
|
|
|
|
|
|
|
|
|
|
| Systemic Treatments and Novel Approaches
|
| Silke Gillessen, MD
|
| As a portion of the ESMO Annual Congress, an Educational Session focused on the management of patients with node-positive locally advanced prostate cancer was held. In this context, Dr. Silke Gillessen discussed the role of systemic therapy and novel, emerging treatment approaches.
|
|
|
|
|
|
| Phase 1b/2 Study of Sabizabulin (VERU-111), an Androgen Receptor Transport Disruptor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Receptor Targeting Agent
|
| Mark Markowski, MD, Ph.D.
|
| Mark Markowski presents data from a phase 1/2 trial of sabizabulin in men with metastatic castration resistant prostate cancer (mCRPC), the VERU-111 trial. These data have formed the basis of a phase II trial (VERACITY) based on evidence from this phase Ib/II clinical trial that oral 63mg daily dosing of sabizabulin has a favorable safety profile and chronic dosing is feasible.
|
|
|
|
|
|
|
|
|
|
|
| Bipolar Androgen Therapy (BAT) Plus Olaparib in Men With Metastatic Castration-Resistant Prostate Cancer
|
| Michael Schweizer, MD
|
| In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Schweizer described a single-center phase II trial testing olaparib in combination with Bipolar Androgen Therapy (BAT) for men with metastatic castration-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
| Final Results of Phase I/II Trial of Fractionated Dose 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| Scott Tagawa, MD |
| Scott Tagawa reports the results of a phase I/II study of dose-escalation study of a fractionated (dose-dense) treatment regime of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). Previously reported, the initial phase I data from this study demonstrated no evidence of short-term dose-limiting toxicity. |
|
|
|
|
|
| PRINCE: Interim Analysis of the Phase Ib Study of 177Lu-PSMA-617 in Combination With Pembrolizumab for Metastatic Castration Resistant Prostate Cancer
|
| Shahneen K. Sandhu, MBBS FRACP
|
| At the ESMO Annual Congress Dr. Shahneen Sandu presented the preliminary results based on an interim analysis of the PRINCE trial assessing the role of 177-Lu-PSMA-617 in combination with pembrolizumab in men with metastatic castration-resistant prostate cancer.
|
|
|
|
|
|
|
